Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years
- PMID: 20129072
- DOI: 10.1016/S1386-6532(09)70294-X
Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years
Abstract
Background: Currently, the German cervical cancer screening program encompasses an annual cytological Papanicolaou (Pap) smear. However, primary screening for cervical cancer using human papillomavirus (HPV) DNA testing detects cervical pre-cancerous lesions with a significantly higher sensitivity than the Pap smear-based cytology.
Objectives: In order to develop viable modalities for primary cervical screening incorporating DNA testing for high-risk (HR) types of HPV, we started a pilot project in the city of Wolfsburg, Germany, in February 2006. This program provided a risk-adapted HPV testing-based strategy with defined patient pathways and extended screening intervals for women of 30 years or older. We report here the data of a 3-year follow-up.
Study design: In the context of the usual routine screening at their office-based gynecologists, women were offered conventional cytology plus the Hybrid Capture 2 (HC2) HPV DNA test. Women with inconspicuous cytological findings (Pap I/II) and negative HC2 test were re-tested after 5 years but continued their annual gynecological examinations. When cytology and HC2 were positive, women were immediately referred to colposcopy. In women with a negative cytology but positive HC2 test, Pap smear was repeated after 6 mo and HC2 testing after 12 mo, and women were called for colposcopy if the HC2 test was persistently positive.
Results: From February 2006 to December 2008, 16,724 women agreed to participate in the project. Overall, 906 (5.41%) had positive HC2 results and 338 (2.02%) showed atypical Pap smears at recruitment. There were 417 (2.48%) women referred for colposcopy, 104 of whom were diagnosed with cervical intraepithelial neoplasia (CIN) 3 or worse, including 8 invasive cancers and 8 adenocarcinoma in situ (ACIS). No case of CIN 3 or worse occurred in HC2 negative women.
Conclusions: The presented risk-adapted Wolfsburg Cervical Cancer Prevention Project ("Wolfsburg Model") has been shown to be effective and feasible in identifying women at risk and for avoiding unnecessary procedures for those who are double negative, thus allowing longer screening intervals and cost savings. Acceptance rates for the program were high for both participating women and gynecologists.
Copyright 2009 Elsevier B.V. All rights reserved.
Similar articles
-
Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.J Clin Virol. 2009 Nov;46 Suppl 3:S11-5. doi: 10.1016/S1386-6532(09)70295-1. J Clin Virol. 2009. PMID: 20129068
-
Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9. J Natl Cancer Inst. 2009. PMID: 19903804 Clinical Trial.
-
The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230. Health Technol Assess. 2014. PMID: 24762804 Free PMC article. Clinical Trial.
-
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Vaccine. 2012. PMID: 23199969 Review.
-
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Vaccine. 2008. PMID: 18847555 Review.
Cited by
-
Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84--results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany.BMC Infect Dis. 2013 Mar 13;13:135. doi: 10.1186/1471-2334-13-135. BMC Infect Dis. 2013. PMID: 23497108 Free PMC article.
-
Incidence Trends of Cervical Cancer and Its Precancerous Lesions in Women of Central Switzerland from 2000 until 2014.Front Med (Lausanne). 2018 Mar 16;5:58. doi: 10.3389/fmed.2018.00058. eCollection 2018. Front Med (Lausanne). 2018. PMID: 29616221 Free PMC article.
-
Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.BMC Infect Dis. 2012 Jan 26;12:25. doi: 10.1186/1471-2334-12-25. BMC Infect Dis. 2012. PMID: 22280073 Free PMC article.
-
Patterns of persistent genital human papillomavirus infection among women worldwide: a literature review and meta-analysis.Int J Cancer. 2013 Sep 15;133(6):1271-85. doi: 10.1002/ijc.27828. Epub 2012 Oct 11. Int J Cancer. 2013. PMID: 22961444 Free PMC article.
-
Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma.Oncol Lett. 2017 Aug;14(2):2427-2431. doi: 10.3892/ol.2017.6435. Epub 2017 Jun 21. Oncol Lett. 2017. PMID: 28781678 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials